Vident Advisory LLC Invests $520,000 in Kenvue Inc. $KVUE

Key Points

• Vident Advisory LLC purchased 21,695 shares of Kenvue Inc., valued at approximately $520,000, during the first quarter, adding to institutional interest in the stock, which is 97.64% owned by institutional investors and hedge funds.
• Kenvue reported earnings of $0.29 per share for the last quarter, slightly exceeding analyst expectations, but revenue decreased by 4.0% year-over-year to $3.84 billion.
• The company declared a quarterly dividend of $0.2075, reflecting a yield of 4.5%, an increase from its previous dividend and indicating commitment to returning value to shareholders.

Vident Advisory LLC bought a new position in Kenvue Inc. (NYSE:KVUE - Free Report) during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 21,695 shares of the company's stock, valued at approximately $520,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Cambridge Investment Research Advisors Inc. raised its stake in Kenvue by 4.0% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 106,140 shares of the company's stock worth $2,545,000 after buying an additional 4,034 shares during the period. IFP Advisors Inc increased its holdings in shares of Kenvue by 25.3% in the first quarter. IFP Advisors Inc now owns 15,278 shares of the company's stock worth $369,000 after acquiring an additional 3,081 shares in the last quarter. Starboard Value LP acquired a new stake in shares of Kenvue during the fourth quarter worth about $467,864,000. Kingswood Wealth Advisors LLC bought a new position in shares of Kenvue during the 1st quarter valued at about $413,000. Finally, FORA Capital LLC acquired a new position in shares of Kenvue in the 1st quarter valued at approximately $981,000. 97.64% of the stock is owned by institutional investors.

Kenvue Stock Up 2.6%

NYSE KVUE traded up $0.47 during trading hours on Tuesday, hitting $18.90. 39,516,199 shares of the company traded hands, compared to its average volume of 21,148,226. The stock has a market capitalization of $36.27 billion, a price-to-earnings ratio of 25.54, a P/E/G ratio of 2.65 and a beta of 0.83. Kenvue Inc. has a twelve month low of $17.15 and a twelve month high of $25.17. The business's 50-day moving average is $21.28 and its 200-day moving average is $22.33. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.68 and a current ratio of 0.98.

Kenvue (NYSE:KVUE - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported $0.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.28 by $0.01. Kenvue had a net margin of 9.37% and a return on equity of 20.06%. The firm had revenue of $3.84 billion for the quarter, compared to analyst estimates of $3.94 billion. During the same period in the prior year, the firm posted $0.32 earnings per share. The company's quarterly revenue was down 4.0% compared to the same quarter last year. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. Sell-side analysts anticipate that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, August 27th. Shareholders of record on Wednesday, August 13th were given a dividend of $0.2075 per share. This represents a $0.83 annualized dividend and a yield of 4.4%. This is a boost from Kenvue's previous quarterly dividend of $0.21. The ex-dividend date was Wednesday, August 13th. Kenvue's dividend payout ratio (DPR) is 112.16%.

Analyst Upgrades and Downgrades

Several analysts have commented on the stock. Evercore ISI dropped their target price on shares of Kenvue from $25.00 to $23.00 and set an "in-line" rating on the stock in a report on Monday. UBS Group cut their price objective on shares of Kenvue from $25.00 to $23.00 and set a "neutral" rating on the stock in a research report on Thursday, July 17th. Barclays reduced their target price on shares of Kenvue from $23.00 to $22.00 and set an "equal weight" rating for the company in a research note on Tuesday, July 15th. Citigroup dropped their price target on Kenvue from $24.50 to $22.00 and set a "neutral" rating on the stock in a research note on Tuesday, July 15th. Finally, Bank of America cut their target price on Kenvue from $27.00 to $25.00 and set a "buy" rating on the stock in a research note on Tuesday, July 15th. Five investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $24.21.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.